Comparison of efficacy of Infliximab and Etanercept on Rheumatoid Arthritis patients

 This study aimed to compare the efficacy of infliximab and etanercept in rheumatoid arthritis (RA) patients to help clinicians select the most effective treatment options. This was a cross sectional study conducted in Urmia, Iran, from March ۲۱, ۲۰۱۷, to February ۲۰, ۲۰۱۸. Data was collected by checklists from RA patients referred to the Rheumatology Clinic of Urmia Imam Khomeini Hospital who were receiving either infliximab or etanercept. Inclusion criteria were a diagnosis of RA according to the revised ۲۰۱۶ criteria of the American College of Rheumatology (ACR)/European League Against Rheumatism, aged over ۱۸, consent to participate in the study, and poor response to other drugs. Both genders were included. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender joint count (TJC), swollen joint count (SJC), and disease activity score (DAS) (۲۸ scores) were analyzed before and after treatment. In a total of ۴۴ eligible patients, ۱۳ patients received infliximab and ۳۱ received etanercept. The mean age was ۵۳.۹۲ ± ۱۰.۹۴ and ۵۲.۸ ± ۶۴.۱۳ years in the infliximab and etanercept groups, respectively. No significant differences were reported concerning ESR (p value = ۰.۹۷) or CRP (p value = ۰.۹۶), while a significant decrease in the infliximab group compared to the etanercept group was demonstrated in terms of DAS۲۸ scores (p value = ۰.۰۲۸), global health (GH)۱ (p value = ۰.۰۰۵), SJC (p value = ۰.۰۰۸), and TJC (p value = ۰.۰۱). This study demonstrated a significant difference between the two groups in the DAS scores ۲۸, SJC, TJC, and GH. 

کلیدواژه ها:

C-reactive protein ، Erythrocyte Sedimentation Rates ، Rheumatoid arthritis